**This article has been corrected:** The correct figures are given below:

The authors declare that these corrections do not change the results or conclusions of this paper.

![Implication of Nox1 in oxaliplatin-induced ROS production and cytotoxicity\
**(D).** Transfected cells were also seeded in white 96-well plates to perform lucigenin assays.](oncotarget-09-26978-g001){#F1}

![Study of calpain expression, activity and implication in oxaliplatin-induced cytotoxicity\
**(C).** The transfected cells were also seeded to perform 72-hour cytotoxicity assays **(C).** Asteriks indicate a statistical significance with *p*\<0.05.](oncotarget-09-26978-g002){#F2}

![Implication of p38 in the resistance to oxaliplatin\
**(B to D).** Cytotoxicity assays were performed with HT29-D4, Rox1 and Rox2 treated with oxaliplatin and incubated in the absence (Control) or in the presence of SB203580, a specific inhibitor of p38 (5 μM).](oncotarget-09-26978-g003){#F3}
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